TGA grants provisional approval to Moderna’s COVID-19 bivalent (SPIKEVAX Bivalent Original/Omicron BA.4-5) booster dose vaccine
Published
Related content
-
TGA grants provisional approval to Pfizer’s COVID-19 bivalent (COMIRNATY Original/Omicron BA.4-5 COVID-19 vaccine) booster dose vaccine
This is the first vaccine provisionally approved by the TGA that is designed to specifically target the Omicron variants BA.4/BA.5 and follows provisional approval of the Pfizer BA.1 Omicron/original bivalent vaccine. -
TGA provisionally approves Pfizer bivalent COVID-19 vaccine for use as a booster dose in adults
The TGA has provisionally approved Pfizer’s bivalent COVID-19 vaccine, tozinameran and riltozinameran (COMIRNATY Original/Omicron BA.1) for use as a booster dose in adults 18 years and over. -
TGA provisionally approves Moderna bivalent COVID-19 vaccine for use as a booster dose in adults
TGA provisionally approves Moderna bivalent COVID-19 vaccine for use as a booster dose in adults